2 AI Surgery Stocks to Buy Hand Over Fist in February

Intuitive Surgical and Medtronic are highlighted as plays on the emerging AI-assisted surgical robotics market: Intuitive installed 1,721 da Vinci robots in 2025 (up from 1,526 in 2024, +~13%), with 11,106 systems installed at year-end (+12% YoY) and procedures using da Vinci up 18% in 2025; the company expects procedures to rise up to 15% in 2026. The article notes recent FDA approval of an AI tool for lung surgery and suggests AI could leverage surgical-robot data, while flagging valuation differences — Intuitive at a P/E of 67 versus Medtronic at 27 — and Medtronic’s 2.8% dividend yield and impending diabetes spin-off as a potential catalyst.

Analysis

Market structure: Surgical robotics winners are installed-base leaders (ISRG) and diversified platforms that bundle services (MDT), plus AI software vendors that can license perioperative models; hospitals and capital equipment less able to fund purchases are losers. ISRG's installed base (11,106 units, +12% YoY) and consumables annuity preserve pricing power, while MDT's diversification and 2.8% yield dampen downside. Supply/demand looks growth-led (surgeries +18% YoY) but is capped by hospital CAPEX cycles; expect 10–20% annual unit growth ceilings absent large reimbursement change.

Risk assessment: Tail risks include FDA or liability setbacks from autonomous procedures, major adverse event litigation, or payor cuts to device reimbursements — each could wipe 20–40% off equity value in 6–24 months. Near term (0–90 days) watch FDA communications and quarterly guidance; medium (3–12 months) risks center on MDT's diabetes spin-off execution; long term (2–5 years) adoption hinges on data access, labeling quality, and liability frameworks. Hidden dependencies: hospital purchasing cycles, surgeon training budgets, and insurer coding updates.

Trade implications: Favor MDT as a core 2–3% long for 6–12 months to capture dividend (2.8%) and potential spin-off re-rate; use a 12% stop. For ISRG, use capital-efficient directional exposure via 9–15 month call spreads (buy 20% OTM, sell 40% OTM) sized 1–2% notional to limit downside versus owning outright. Consider a pair trade: long MDT (1.5%) / short ISRG (1.0%) to express valuation gap; sell 3–6 month covered calls on MDT 8–12% OTM to enhance yield around spin-off.

Contrarian angles: Consensus underestimates legal/regulatory lag and overestimates speed to autonomous surgery — adoption could take 3–7 years, compressing near-term upside for pure-plays like ISRG. Conversely, MDT's spin-off could unlock 15–30% upside if margins rise and multiple rerates; watch for low-cost entrants eroding consumable annuities, and treat any >15% install growth deceleration as a sell signal.

Key Decisions for Investors

• Establish a 2–3% long position in Medtronic (MDT) within 0–30 days to capture the 2.8% dividend and potential 12-month spin-off re-rating; set an initial stop-loss at -12% and target 12–18% total return over 12 months.
• Avoid buying ISRG outright at current rich multiples; instead allocate 1–2% of portfolio to 9–15 month call spreads on Intuitive Surgical (ISRG) with longs ~20% OTM and shorts ~40% OTM to cap premium and retain upside if FDA/autonomy catalysts materialize.
• Implement a pair trade: long MDT 1.5% vs short ISRG 1.0% (dollar-neutral) to play valuation convergence; rebalance after quarterly earnings or any FDA decision, and close if spread narrows by 50% or after 6 months.
• Enhance yield on MDT exposure by selling 3–6 month covered calls 8–12% OTM; monitor regulatory filings and FDA communications over next 30–60 days and exit/trim if adverse safety signals or reimbursement code changes occur.